Graph not available
Graph not available

Open Demat Account

50years
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O
left-arrow
Fundamentals
Financials
Shareholding
Resistance/Support
Delivery and Volume
About
Management
News
Similar Stocks
right-arrow

Camlin Fine Sciences Ltd Performance

Today's Low
97.15
arrowIcon
Today's High
100.45
52 Wk Low
88.35
arrowIcon
52 Wk High
186.35


Open

99.6

Traded Value (Cr)

1.94 Cr

Prev. Close

98.6

VWAP

99.58

Volume

3,51,866

Face Value

1

Camlin Fine Sciences Ltd Fundamentals

Market Cap
₹ 1,680 Cr
P/E Ratio (TTM)
0.00
P/B Ratio
1.91
Debt to Equity
0.73
ROE
3.62 %
EPS (TTM)
0.00
Dividend Yield
0.00%
Book Value
52.50

Click here to know more about Fundamentals

Camlin Fine Sciences Ltd Financials

Camlin Fine Sciences Ltd Financials

Camlin Fine Sciences Ltd Shareholding Pattern

Held By Mar 2024 Dec 2023 Sep 2023 Jun 2023
Promoters 48.03 % 48.03 % 48.03 % 16.52 %
Retail 32.75 % 34.18 % 33.23 % 30.41 %
Others 14.76 % 14.05 % 14.39 % 34.50 %
Mutual Funds 2.77 % 2.75 % 2.74 % 8.45 %
FII 1.69 % 0.99 % 1.61 % 10.12 %

Promoters

48.03%

Retail

32.75%

Others

14.76%

Mutual Funds

2.77%

FII

1.69%

Promoters

48.03%

Retail

34.18%

Others

14.05%

Mutual Funds

2.75%

FII

0.99%

Promoters

48.03%

Retail

33.23%

Others

14.39%

Mutual Funds

2.74%

FII

1.61%

Promoters

16.52%

Retail

30.41%

Others

34.50%

Mutual Funds

8.45%

FII

10.12%

Resistance and Support

₹104.45

PIVOT

resistance-arrow
Resistance
First Resistance₹107.200
Second Resistance₹108.950
Third Resistance₹111.700
support-arrow
Support
First Resistance₹102.700
Second Resistance₹99.950
Third Resistance₹98.200
RSI26.750
MACD-1.487
ADX13.029
CCI-176.339

Delivery and Volume

PeriodDelivery Volume Traded Volume Delivery Volume %
Day351,866163,83346.56
Week558,196282,94050.41
1 Month635,052324,01551.69
6 Months548,488283,69151.72

About Camlin Fine Sciences Ltd

Camlin Fine Chemicals Ltd is one of the India's leading manufacturers and exporters of Bulk Drugs, Fine Chemicals and Food Grade products. The company manufactures active pharmaceutical ingredients (API's), food antioxidants and sweeteners. They operate in two business divisions, namely Food Ingredients Division and Industrial products Division. The company's products have applications in processed foods, edible oils, paints, polymers, alternative fuels (biodiesel), rubber, health, and pharmaceuticals. The company has a strong research and development which is focused on bringing in continual improvements on process and products, backward integration and developing innovative products. The research and development is equipped with comprehensive and updated instrumentation for conducting quality analysis, stability studies. The research and development also is equipped to conduct application studies on stability index of edible oils and Bio-diesel. Camlin Fine Chemicals Ltd was originally incorporated on November 30, 1993 as a private limited company with the name of Camlicon Consultants Pvt Ltd. In April 2006, the main object of the company was altered to enable the company to pursue business in Fine Chemicals. They launched a new product namely, 'Sucralose' which is a synthetic sweetener with large demand and attractive price. In June 1, 2006, the name of the company was changed from Camlicon Consultants Pvt Ltd to Camlin Fine Chemicals Pvt Ltd. As per the scheme of arrangement, the fine chemicals division of Camlin Ltd was de-merged and transferred to the company with effect from July 01, 2006. In August 11, 2006, the company was converted into public limited company and the name was changed to Camlin Fine Chemicals Pvt Ltd. The company entered into a joint venture with Viachem LLC USA on 51:49 basis and set up a company namely, Dulcette Technologies LLC for marketing Sucralose, Aspartame and Acesulfame-K and their blends in USA, Canada and Mexico. In March 30, 2007, the equity shares of the company were listed on the Bombay Stock Exchange (BSE). During the year 2007-08, the company increased the production capacity of Chemical & Chemical Products from 1,636 Ltrs/Kgs to 2,476 Ltrs/Kgs. The company acquired the control of Sangam Laboratories Ltd by acquiring 60% of the paid up equity share capital of the company. They invested Rs 5 lakh for controlling interest in the Equity Share Capital of Chemolutions Chemicals Ltd. In February 2008, the company entered into a joint venture agreement with Advanced Aerospace Technologies Inc., USA' to manufacture and market speciality fine chemicals primarily to cater to European and U.S markets. During the year 2008-09, the company expanded the production capacity of Chemical & Chemical Products from 2,476 Ltrs/Kgs to 2,548 Ltrs/Kgs. The company invested Rs 25.50 lakh in Fine Lifestyle Brands Ltd and Rs.5.10 lakh in Fine Renewable Energy Ltd, which represents 51% of equity share capital of each of them. They further invested Rs 92.32 lakh in the share capital of their present subsidiaries, namely Sangam Laboratories Ltd, Chemolutions Chemicals Ltd and Dulcette Technologies LLC, USA. During the year 2009-10, the company expanded the production capacity of Chemical & Chemical Products from 2,458 Ltrs/Kgs to 3,500 Ltrs/Kgs. They are entering the field of Bio technology products and first patented, biotechnology based Natural shelf life enhancing formula for increasing shelf life of Natural farm produce, like fruits, vegetables and flowers. During the year 2011, Chemolutions Chemicals Limited, Fine Lifestyle Brands Limited and Fine Renewable Energy Limited ceased to be subsidiaries of the Company. The Hon'ble High Court Bombay, vide order dated 21st April, 2011 approved Scheme of Amalgamation for merger of Sangam Laboratories Limited, a 100% owned subsidiary with the Company. W.e.f. 27th August, 2011 name of the Company was changed from Camlin Fine Chemicals Limited to Camlin Fine Sciences Limited. The establishment of two major business divisions, namely, Food and Industrial Products was completed. The Company expanded its manufacturing capacity of the food antioxidants, Ascorbyl Palmitate, TBHQ and BHA in 2012-13. In January 2016, it started operations in Central America with the launch of CFS Antioxidantes De Mexico, S.A. de C.V., a 100% subsidiary of Camlin Fine Sciences Ltd., acquired 65% stake in Dresen Química S.A.P.I de C.V, a leading food and feed blend company in Mexico; launched CFS North America, LLC, a 100% owned subsidiary of CFS for manufacturing and selling of customised antioxidant blends; launched Evanil, ethyl vanillin for food and bakery industry. On 15th April, 2016, a 100% wholly owned subsidiary CFS International Trading (Shanghai) Ltd. was incorporated in China (Shanghai) pilot free trade zone to manufacture and deal in speciality chemicals. On 22nd March, 2017, Chemolutions Chemicals Limited (CCL) allotted 62,67,003 equity shares on preferential basis to the Company. Post allotment, the shareholding of Company in CCL was 94.08% and CCL became the subsidiary of the Company. In July 2017, Company through its wholly owned stepdown subsidiary viz. CFS Europe S.p.A. acquired 51% stake in CFS Wanglong Flavours (Ningbo) Co. Ltd. erstwhile Ningbo Wanglong Flavors and Fragrances Company Limited. In April 2018, Company signed a joint venture contract with Pahang Pharma (S) Pte. Ltd., Singapore (Pahang) for incorporating a holding company, shareholding in the proportion of 51:49, named CFS Pahang Asia Pte. Ltd. in Singapore. In 2019, the Company reverse merged its wholly owned subsidiary in Mauritius viz., CFCL Mauritius Private Limited into CFS Europe Spa, Italy effective 25th June, 2019 and resultant to this merger, CFS Europe Spa became a wholly-owned subsidiary. The reverse merger of CFS Antioxidnates De Mexico De CV with Dresen Quimica SAPI De CV was effective 31st January, 2019 and resultant to reverse merger, CFS Antioxidantes De Mexico S.A. de. C.V. ceased to be the wholly-owned subsidiary of the Company from the aforementioned date. As a part of this initiative, Company acquired a company situated in Southern part of India, namely, AlgalR Nutrapharms Private Limited (AlgalR) which manufactures oils containing Omega 3 Fatty Acids. The company embarked upon its largest greenfield expansion in 2018 in Dahej, Gujarat for a green-technology-based DiPhenol plant for a 10,000 MT Di-Phenol facility. And in September 2020, it announced the commercial production of Hydroquinone and Catechol. During the financial year 2021-22, AlgalR NutraPharms Private Limited and CFS De Mexico Blends SAPI De CV became subsidiaries and Fine Lifestyle Brands Limited has ceased to be a Associate of the Company.

Managing Director

Ashish S Dandekar

Founded

1993

NSE Symbol

CAMLINFINE

Camlin Fine Sciences Ltd Management

NameDesignation
Ashish S DandekarChairman & Managing Director
Nirmal V MomayaManaging Director
Anagha S DandekarDirector
Arujun S DukaneExecutive Director (Technical)
Amol ShahIndependent Director
Sutapa BanerjeeIndependent Director
Mahabaleshwar G PalekarIndependent Director
Harsha RaghavanDirector
Conrad D SouzaIndependent Director
Pradip M. KanakiaIndependent Director
Rahul SawaleVice President & CS

Camlin Fine Sciences Ltd News

Camlin Fine Sciences schedules board meeting
On 20 May 2024
Camlin Fine Sciences Ltd leads gainers in 'A' group
Lloyds Engineering Works Ltd, IIFL Finance Ltd, Asahi India Glass Ltd and NCC Ltd are among the other gainers in the BSE's 'A' group today, 05 April 2024.
Camlin Fine Sciences Ltd leads losers in 'A' group
Pfizer Ltd, Dwarikesh Sugar Industries Ltd, Mold-Tek Packaging Ltd and Tega Industries Ltd are among the other losers in the BSE's 'A' group today, 28 March 2024.
Camlin Fine Sciences allots 10,400 equity shares under ESOP
Camlin Fine Sciences reports consolidated net loss of Rs 11.79 crore in the December 2023 quarter
Sales decline 0.50% to Rs 385.89 crore
Camlin Fine Sciences to table results
On 9 February 2024
Camlin Fine Sciences Ltd leads gainers in 'A' group
Alembic Pharmaceuticals Ltd, New India Assurance Company Ltd, India Cements Ltd and Great Eastern Shipping Company Ltd are among the other gainers in the BSE's 'A' group today, 30 November 2023.
Camlin Fine Sciences Ltd leads losers in 'A' group
Rategain Travel Technologies Ltd, Sobha Ltd, Harsha Engineers International Ltd and Macrotech Developers Ltd are among the other losers in the BSE's 'A' group today, 07 November 2023.
Camlin Fine Sciences reports consolidated net loss of Rs 19.38 crore in the September 2023 quarter
Sales decline 16.01% to Rs 405.88 crore
Camlin Fine Sciences extends closure of its Diphenol Plant in Italy

Similar Stocks

CompanyMarket CapMarket PriceP/E Ratio
PIDILITIND₹ 1,43,176 Cr
₹ 2,837.35
(0.79 %)
79.86
SRF₹ 69,336 Cr
₹ 2,291.35
(-2.04 %)
50.45
LINDEINDIA₹ 65,436 Cr
₹ 7,575.85
(-1.27 %)
155.53
FLUOROCHEM₹ 36,324 Cr
₹ 3,197.25
(-3.31 %)
86.82
DEEPAKNTR₹ 34,152 Cr
₹ 2,435.80
(-2.72 %)
81.65

Camlin Fine Sciences Ltd FAQ

By opening a demat account and having your KYC papers confirmed online, you may simply purchase Camlin Fine Sciences Ltd shares in BlinkX

The share price of any stock is volatile and changes during the day due to a variety of variables. Camlin Fine Sciences Ltd's share price is ₹100.20 as of May 10, 2024

Camlin Fine Sciences Ltd's P/E ratio is 0.00 times as of May 10, 2024.

Camlin Fine Sciences Ltd's most recent financial reports indicate a price-to-book ratio of 1.91, showing the company's stock market valuation in relation to the value of its real assets.

Market capitalisation, often known as market cap, is the market value of all outstanding shares of a publicly listed corporation. Camlin Fine Sciences Ltd's market is 1,681 Cr as on May 10, 2024.

The current financial records of Camlin Fine Sciences Ltd show a 3.62% ROE, showing great financial performance and effective capital utilisation, making it a significant statistic for investors.

The 52-week high/low price of a Camlin Fine Sciences Ltd stock is the highest and lowest price at which it has traded over that period (about one year) and is used as a technical indicator. Camlin Fine Sciences Ltd's 52-week high and low as of May 10, 2024 are ₹100.45 and ₹97.15 respectively.

As of the Mar 2024 quarter, the promoter shareholding in Camlin Fine Sciences Ltd stands at 48.03%. During the same period, Institutional Investors have shown a slight increase in their holdings, rising from 0.99% to 1.69%.